The Tisch Cancer Institute is forging a new path in genomics, and embracing the unprecedented opportunities that are transforming biomedicine. At the same time, we are maintaining The Mount Sinai Medical Center’s tradition of world-class research by bringing together the best cancer clinicians and researchers.

Mount Sinai’s most recent recruits include Eric Schadt, PhD, Director of the Institute for Genomics and Multiscale Biology, and Carlos Cordon-Cardo, MD, PhD, Chair of Pathology. Under Dr. Schadt, the Institute for Genomics will serve as a center of genomics research, collaborating with Mount Sinai’s disease-oriented and core-technology based institutes. Dr. Cordon-Cardo will oversee Mount Sinai’s major effort in cutting-edge molecular pathology. A leader in the mechanism of tumor suppression, his research has focused on analyses of multi-drug resistance and alterations of tumor suppressor genes in human cancer.

Drs. Schadt and Cordon-Cardo join The Tisch Cancer Institute’s renowned group of laboratory-based and clinical investigators who are leading research into the prevention, diagnosis, and treatment of cancer. When Mount Sinai’s 550,000 square-foot Center for Science and Medicine (CSM) opens in fall 2012, it will provide us with unparalleled opportunities to continue our role as a national leader in the field of cancer. The Tisch Cancer Institute will occupy almost half of the new CSM. Our laboratory scientists and clinical investigators will be housed next to each other, helping to facilitate their collaboration.

Fostering a close-knit community of researchers is emblematic of Mount Sinai’s commitment to translational research, which is in our DNA, and the reason why Mount Sinai School of Medicine was created more than four decades ago. Today, we are putting the processes and platforms in place to help us make the necessary breakthroughs in all aspects of cancer, and bring these discoveries to the patient’s bedside.
Some of the highlights of the new Cancer Institute at CSM include:

**Expanded clinical space**
The third and fourth floors of the CSM will house the newly expanded Ruttenberg Treatment Center, which will more than double in size, providing infusion bays, exam rooms, laboratory testing, and an onsite pharmacy (including dedicated research pharmacy). Social services, including counseling and support groups, will also be offered in this space. Expanded radiation oncology facilities will be located on the lower floor of CSM. Radiation Oncology will have the capacity for three additional linear accelerators.

**State-of-the-art cancer imaging**
The expanded Translational and Molecular Imaging Institute (TMII) and Cancer Radiology Department will be adjacent to each other on the lower level of CSM. TMII’s state-of-the-art, multi-user core research facility in CSM will include 1.5T, 3.0T, and 7.0T MRI, MRI/PET, PET/CT, dual kvp CT, and Spectral CT for use in translational patient studies. In addition, a small animal unit will house high-field MRI units, micro SPECT/PET/CT, and ultrasound, as well as advanced postprocessing and molecular imaging capabilities.

**New research space**
The fifth and sixth floors will be dedicated to cancer research, with expanded laboratory space that will provide room for the recruitment of approximately 20 cancer scientists and their teams. In addition to laboratory space, the CSM will allow for the expansion and development of shared resources that will be utilized by members of The Tisch Cancer Institute.

---

**NEW FACES**

**Carlos Cordon-Cardo, MD, PhD**

Carlos Cordon-Cardo, MD, PhD, a renowned physician-scientist, and pioneer in oncologic molecular pathology, has been appointed Chair of the Department of Pathology at The Mount Sinai Medical Center. Dr. Cordon-Cardo is a distinguished leader in the mechanism of tumor suppression, particularly in bladder cancer, prostate cancer, and soft-tissue sarcomas. His research focuses on understanding the cooperative effects of mutations of cell-cycle regulation, and genes that prevent cell death in cancer patients. Dr. Cordon-Cardo helped create the systems pathology platform, which uses systems biology to create mathematical models of the interaction and behavior of cancer cells. This helps scientists determine tumor pathogenesis and predict clinical outcomes. In his new position, Dr. Cordon-Cardo will draw upon his experience as an investigator, administrator, and educator, and work to enhance the Pathology Department’s clinical and research programs in cancer. Prior to joining Mount Sinai, Dr. Cordon-Cardo was Vice Chair of Pathology, Professor of Pathology and Urology, and Associate Director for Infrastructure at the Herbert Irving Comprehensive Cancer Center at Columbia University College of Physicians and Surgeons.

**Eric E. Schadt, PhD**

Eric E. Schadt, PhD, one of the world’s foremost experts in computational biology, recently joined The Mount Sinai Medical Center as Director of the Institute for Genomics and Multiscale Biology. The Institute is being set up in partnership with Pacific Biosciences of California (PacBio) where he will continue to serve as Chief Scientific Officer. An expert in large-scale sequence variation, molecular profiling, and clinical data in disease populations, Dr. Schadt’s research has provided novel insights into how massive amounts of data can be used to understand the complexity of diseases and lead to more informed decisions about drug discovery. He has also contributed to a number of important findings on the genetic basis of diabetes and obesity. In his dual roles at Mount Sinai and PacBio, Dr. Schadt will oversee a hub of genomics research, which will be at the forefront of the revolution in genetics and genomic sciences. He will foster multidisciplinary collaboration in areas such as newborn screening for rare genetic disorders, infectious diseases, and cancer. Dr. Schadt is a founding member of Sage Bionetworks, an open-access genomics initiative. Before joining PacBio in 2009, he was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc.
Cancer Immunotherapies
The cancer immunology and immunotherapy (CII) research program was developed by The Tisch Cancer Institute in collaboration with the Immunology Institute to explore the role of inflammation in cancer progression and cancer therapy. The goal of the CII program is to dissect the inflammatory pathways that drive cancer progression and metastasis, and identify new immune targets for the treatment of cancer patients. The focus is on identifying synergistic strategies that combine cytotoxic regimens such as chemo- and radiotherapy and immune therapies to inhibit tumor growth and relapses.

Open clinical trials in cancer immunotherapies:
• Phase II study of gemcitabine, cisplatin, plus ipilimumab for treatment of metastatic urothelial cancer (PIs: Matthew Galsky, MD; and William Oh, MD)
• Host dendritic cell infusion in allograft patients with advanced hematologic malignancies (PIs: Keren Osman, MD; Miriam Merad, MD, PhD; Anna Karolina Palucka, MD, PhD)
• Biomarker of HPV-specific immune responses in patients with virally-mediated head and neck cancer treated with radiation-based therapy (PIs: Andrew Sikora, MD, PhD; Marshall Posner, MD)

Genitourinary Cancers
Staffed by talented physicians and scientists who have access to the technological resources to advance diagnostics and develop safer, more effective therapies, The Tisch Cancer Institute’s Genitourinary (GU) Medical Oncology Program offers novel approaches to research and patient care. To achieve our goal of creating effective new personalized diagnostic techniques and treatments, we are concentrating in three related areas: translational discoveries, clinical trials, and the development of a biorepository. We believe that bringing visionary basic scientists and clinicians together is critical to advancing GU cancer biology and patient treatment.

Open clinical trials in genitourinary cancer:
• Predicting Response to Platinum Chemotherapy in Metastatic Castration Resistant Prostate Cancer (mCRPC) Using a Genomic Signature for “BRCAness”: A Phase II prospective open label clinical trial of second line satraplatin in men with mCRPC (PI: William Oh, MD)
• Phase I/II Trial of Gemcitabine + Cisplatin + Lenalidomide in Patients with Metastatic Urothelial Carcinoma (PI: Matthew Galsky, MD)

Head and Neck Cancer
The Head and Neck Cancer program at The Tisch Cancer Institute provides each patient with personalized care, taking into account the biology of the cancer condition, the patient’s medical issues and history, and the goals of his or her therapy. We offer a range of therapies, and pay attention to cutting-edge diagnosis, treatment, and management of head and neck cancers. Through our broad portfolio of head and neck cancer clinical trials, we hope to develop new agents that will enable us to better manage our patients’ diseases.

Open clinical trials in head and neck cancer:
• Transoral Robotic Surgery (TORS): Pharyngeal, Laryngeal and Tracheal Surgery with Flexible Carbon Dioxide Laser (PI: Eric Genden, MD)
• Phase I Study of Cabazitaxel-PF Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PI: Krzysztof Misiukiewicz, MD)
• HPV Oral Transmission Study in Partners Over Time (HOTSPOT) (PI: Marshall Posner, MD)

Hematological Malignancies
The Tisch Cancer Institute’s hematological malignancies program integrates basic science, stem cell biology, and translational research. The program is unique in that it focuses on several diseases—including myeloproliferative neoplasms and myelodysplastic disorders—that have many elderly patients who...
face a limited number of treatment options. Mount Sinai is home to one of the leading programs in the country for the diagnosis and treatment of multiple myeloma, and is utilized by myeloma patients from around the world.

**Open clinical trials in hematological malignancies:**

- A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi) in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (PI: Ronald Hoffman, MD)

- A Phase I/II Study to evaluate safety and efficacy of multiple doses of BT062 in subjects with relapsed or relapsed/refractory multiple myeloma (PI: Sundar Jagannath, MD)

**Hepatocellular Carcinoma**

The Hepatocellular Carcinoma (HCC) program at Mount Sinai is an international leader in clinical and translational research, having been the highest enrolling program in the SHARP trial, which resulted in approval of sorafenib as the first molecular targeted therapy for this neoplasm. Mount Sinai's HCC program offers the largest clinical trials program for the disease in the United States.

**Open clinical trials in Hepatocellular Carcinoma:**

- Phase III randomized, placebo trial of Sorafenib + Erlotinib v. Placebo as 1st Sys Tx HCC (STORM) (PI: Josep Llovet, MD)

- Phase III study of Brivanib + Best Supportive Care (BSC) v. Placebo Plus BSC in patients with HCC (BRISK) (PI: Josep Llovet, MD)

- Sorafenib or Placebo in combination with TACE for intermediate Stage IIIC (SPACE) (PI: Josep Llovet, MD)